The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanchez-Lockhart, M.
Right arrow Articles by Miller, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanchez-Lockhart, M.
Right arrow Articles by Miller, J.
The Journal of Immunology, 2006, 176: 4778-4784.
Copyright © 2006 by The American Association of Immunologists

Engagement of CD28 Outside of the Immunological Synapse Results in Up-Regulation of IL-2 mRNA Stability but Not IL-2 Transcription1

Mariano Sanchez-Lockhart and Jim Miller2

David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences and the Department of Microbiology and Immunology, University of Rochester, Rochester, NY 14642


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
During T cell activation by APC, CD28 is colocalized with TCR in the central supramolecular activation cluster (cSMAC) region of the immunological synapse. CD28 signaling through PI3K results in the recruitment of protein kinase C (PKC){theta} to the cSMAC, activation of NF-{kappa}B, and induction of IL-2 transcription. These results suggest that localized engagement of CD28 within the cSMAC may be required for CD28 activation and/or signal integration with TCR signals. To test this model we have examined the mechanism of CD28-mediated induction of IL-2 secretion when CD28 is engaged outside of the immunological synapse. CD4 T cells were stimulated with Ag presented by B7-negative APC and CD28 costimulation was provided in trans by anti-CD28-coated beads or by class II-negative, B7-positive cells. We show that induction of IL-2 secretion under these conditions did not require expression of PKC{theta} and did not induce NF-{kappa}B activation or IL-2 transcription. In contrast, CD28 costimulation in trans did induce IL-2 mRNA stability, accounting for the up-regulation of IL-2 secretion. These data indicate that the ability of CD28 to up-regulate IL-2 transcription requires colocalization of TCR and CD28 at the plasma membrane, possibly within the cSMAC of the immunological synapse. In contrast, the ability of CD28 to promote IL-2 mRNA stability can be transduced from a distal site from the TCR, suggesting that signal integration occurs downstream from the plasma membrane. These data support the potential role of trans costimulation in tumor and allograft rejection, but limit the potential functional impact that trans costimulation may have on T cell activation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
It has been shown that T cell costimulation through CD28 can have a dramatic impact on T cell activation, differentiation, and tolerance (1, 2, 3, 4). T cell stimulation in the absence of CD28 leads to T cell anergy rather than activation and only costimulation through CD28, and not other costimulatory molecules, can protect against anergy induction (5, 6). CD28 costimulation leads to a dramatic up-regulation in IL-2 expression mediated by both enhanced transcription and induction of mRNA stabilization (7, 8). CD28 costimulation also plays an important role in T cell survival, inducing expression of the antiapoptotic protein Bcl-xL (9) and regulating the metabolic activity of T cells (10). Finally, CD28 plays a key role on the generation of Th2 responses (11). In combination, these effects resulted in a dramatic loss in T cell expansion and effective immune responses in CD28-deficient mice.

Despite the well-recognized functional importance of CD28, the biochemical signaling pathways induced downstream of CD28 are still not completely understood (1, 4). This result may be due, in part, to the ability of CD28 to amplify TCR-initiated signaling events (1). CD28 has been shown to lower the threshold of TCR engagement (12) and T cell responses are diminished, but not absent, in CD28-deficient T cells. Both protein profiling of signaling intermediates (13) and genetic profiling of changes in gene expression (14, 15) have suggested that CD28 costimulation functions primarily to modify those signaling pathways that can be induced by the TCR itself and it has been difficult to identify a unique contribution of CD28.

One potential site where CD28 could impact on TCR signaling is within the central supramolecular activation cluster (cSMAC)3 of the immunological synapse (16, 17, 18, 19). Although T cells express a number of protein kinase C (PKC) isoforms, PKC{theta} is selectively activated and recruited to the immunological synapse, where it is colocalized with TCR and CD28 in the cSMAC (20, 21). PKC{theta} plays an essential role in transducing TCR-mediated activation of NF-{kappa}B (22, 23, 24). Expression of CD28 is required for the targeting of PKC{theta} to the cSMAC. In the absence of CD28, PKC{theta} is recruited to the immunological synapse, but it is diffusely distributed across the synapse and is not focused into the cSMAC (25, 26). This disruption in PKC{theta} localization in the absence of CD28 correlates with a loss in PKC{theta}-dependent induction of NF-{kappa}B and IL-2 transcription. Interestingly, all of these functions of CD28 (recruitment of PKC{theta} to the cSMAC, activation of NF-{kappa}B, and up-regulation of IL-2 transcription) are lost by a single amino acid mutation of the PI3K interaction site in the cytosolic tail of CD28 (26). These results suggest that CD28-mediated activation of PI3K leads to a localized concentration of phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the synapse that results in the recruitment and activation of PKC{theta} and subsequent induction of IL-2 transcription. Recent data on the recruitment of a GFP-PH domain fusion protein to the synapse (27, 28, 29) and the possible role for phosphoinositide-dependent protein kinase PDK1 in PKC{theta} activation (23) support this model. Taken together, these results suggest that signal integration between TCR and CD28 may occur within and through the spatial organization of proteins in the immunological synapse.

In addition, CD28 has been shown to transduce costimulatory signals in trans, i.e., from a separate site on the cell surface from TCR engagement. This was first shown by the ability of MHC-disparate APC to provide T cell costimulation and protect against clonal anergy (30). Later, trans costimulation was shown to be mediated through CD28 (31, 32, 33). In vivo, trans costimulation may contribute to T cell activation to Ags expressed by nonhemopoietic cells, such as in tumor or allograft rejection (34). These functional studies suggested that CD28 did not have to be localized to the immunological synapse to provide costimulatory signals to T cells. In this study we show that when CD28 is provided in trans, the induction of IL-2 expression is not mediated through PKC{theta} activation and induction of IL-2 transcription. Rather, CD28 costimulation in trans effectively enhances T cell activation through the induction of IL-2 mRNA stability.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Cell lines and T cell stimulation

6132 Pro cell transfectants expressing class II (I-Ad) in combination with ICAM-1 (ProAd-ICAM) or with ICAM-1 and B7-1 (ProAd-ICAM-B7) (35) and the class II-negative fibroblast L cell line (DAP-3), which constitutively expresses B7 (36), were maintained in DMEM (Invitrogen Life Technologies) supplemented with 10% FCS, 2 mM glutamine, 0.1 mM nonessential amino acids, 40 µg/ml gentamicin, and 50 µM 2-ME. To maintain selection of transfected genes, G418 (200 µg/ml) and/or MXH (6 µg/ml mycophenolic acid, 250 µg/ml xanthine, 15 µg/ml hypoxanthine) were added as appropriate. CD4-positive lymph node T cells were purified as previously described (35) from wild-type (WT), CD28-deficient, PKC{theta}-deficient (24), and IL-2-luciferase reporter transgenic (26, 37, 38) DO11.10 TCR transgenic mice. Freshly isolated DO11.10 T cells were assayed directly or after in vitro activation with Ag presented by irradiated BALB/c splenocytes under neutral conditions. Previously activated T cells are essential 100% CD4 and KJ1.26-positive and contain a mixture of IL-4 and IFN-{gamma}-secreting cells (typically 10–20% IL-4 and 40–60% IFN-{gamma}-secreting). Previously activated T cells were rested for 7–14 days before use in experiments. For retroviral transduction, freshly isolated DO11.10 T cells were stimulated with Ag as shown and 1 day later were transduced with a retrovirus encoding an NF-{kappa}B p65-GFP fusion protein (39). For trans costimulation with anti-CD28-coated beads, surfactant-free surface latex beads were first coated with goat anti-Syrian hamster Ab at room temperature overnight, and after blocking with BSA, anti-CD28 mAb (37.51) was captured at room temperature for 4 h. T cell to bead ratio was 1:3 in all experiments performed.

IL-2 ELISA and luciferase assay

T cells were stimulated with Ag in the absence of CD28 costimulation (ProAd-ICAM), in the presence of CD28 in cis (ProAd-ICAM-B7), or by providing CD28 in trans (ProAd-ICAM with anti-CD28-coated beads or B7-positive L cells). Supernatants were collected at 24 or 48 h and IL-2 was measured by a capture ELISA. For luciferase activity, T cells were stimulated under the same conditions, but after 24 h of stimulation, T cells were lysed and luciferase activity was determined according the manufacturer’s instructions (Promega).

Immunofluorescence microscopy

T cells were centrifuged with peptide-pulsed APC with and without anti-CD28-coated beads or B7-positive L cells for 20 s at relative centrifugal force of 2000. The cell pellet was incubated for 5 min at 37°C, resuspended in DMEM, and plated on poly-L-lysine-coated coverslips for 10 min at 37°C. Cells were fixed in 3% (w/v) paraformaldehyde, and stained with rabbit anti-PKC{theta} (C-18; Santa Cruz Biotechnology) and anti-rabbit-FITC or anti-rabbit-Cy3 (Jackson ImmunoResearch Laboratories). For NF-{kappa}B nuclear localization, the incubation time on poly-L-lysine-coated coverslips was increased to 25 min and cells were fixed in 3% (w/v) paraformaldehyde and permeabilized in 0.3% Triton X-100. Localization of NF-{kappa}B was detected with rabbit anti-p65 (SC-109; Santa Cruz Biotechnology) or in retrovirally infected cells by detection of the p65-GFP fusion protein. After staining, nuclei were labeled with Hoestch dye. Samples were analyzed on a Zeiss Axiovert microscope controlled by SlideBook software (Intelligent Imaging Innovations).

Real-time RT-PCR

Activated T cells (1 x 106) were stimulated with Ag presented by ProAd-ICAM alone, ProAd-ICAM, and anti-CD28-coated beads (trans costimulation) or ProAd-ICAM-B7 (cis costimulation) for 4 h and further IL-2 transcription was inhibited by the addition of 1.0 µg/ml cyclosporin A (Calbiochem). Total RNA was isolated using TRIzol (Invitrogen Life Technologies) and reverse transcribed into cDNA. The level of IL-2 mRNA was determined by real-time PCR following normalization to a T cell-specific gene, CD3{delta}, using the {Delta}{Delta}CT method for relative quantitation with IL-2 mRNA levels in the absence of Ag as the calibrator. TaqMan probe and primers for IL-2 and CD3{delta} were obtained from Applied Biosystems.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
CD28 costimulation in trans is not mediated through PKC{theta} activation

CD28 has the unique ability among potential costimulatory molecules to function when it is engaged on the T cell at a site that is distal to the TCR (in trans). CD28 costimulation in trans can lead to the up-regulation of IL-2 secretion (Fig. 1), but it is not clear how signals from CD28 in trans are integrated with TCR-derived signals. We have recently found that there are two independent pathways for CD28 costimulation (26). One pathway is mediated through PI3K and leads to the cSMAC localization of PKC{theta}, activation of NF-{kappa}B, and the transcriptional up-regulation of IL-2. The second pathway is not dependent on CD28-mediated activation of PI3K and results in the up-regulation of IL-2 secretion through the induction of IL-2 mRNA stability. To determine whether CD28 in trans can induce one or both of these pathways, we initially examined the localization of PKC{theta} within the immunological synapse (Fig. 2). WT DO11.10 T cells were stimulated with Ag presented by ProAd-ICAM. LFA-1 costimulation in the absence of CD28 costimulation can induce PKC{theta} recruitment to the immunological synapse, but not to the cSMAC (26). To determine whether CD28 must be engaged within the immunological synapse to impart this effect, PKC{theta} localization was assayed after providing CD28 costimulation in trans. When anti-CD28-coated beads were added to allow the formation of T cell:APC:bead conjugates, the level of IL-2 secretion was increased (Fig. 1), but PKC{theta} remained diffusely localized to the synapse and was not focused into the cSMAC (Fig. 2C). Instead, recruitment of PKC{theta} to the site of TCR engagement at the APC was actually diminished (Fig. 2B). In no case was PKC{theta} detected at the site of CD28 engagement, whether the T cells were in contact with beads alone or with both APC and beads. To confirm that trans costimulation mediated by anti-CD28-coated beads mimicked CD28 engagement by natural ligand, B7-positive, class II-negative L cells were used to provide CD28 costimulation in trans. CD4+ T cells costimulated in trans by L cells displayed the same phenotype, as was observed when CD28 costimulation was provided by anti-CD28-coated beads (Fig. 2). Thus, unlike when CD28 costimulation was provided at the same site as TCR engagement, CD28 costimulation in trans did not direct the localization of PKC{theta} to the cSMAC.


Figure 1
View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 1. CD28 costimulation in trans promotes IL-2 secretion. Previously activated DO11.10 T cells were unstimulated (–Ag) or stimulated with Ag (+) presented by ProAd-ICAM (–CD28), ProAd-ICAM and anti-CD28-coated beads (trans), or ProAd-ICAM-B7 (cis). T cells were cultured for 48 h, and supernatants were assayed for IL-2 secretion by capture ELISA. Data are the mean and SD from a total of eight independent experiments. Both CD28 costimulation in trans and in cis enhanced IL-2 secretion (p = 0.002 and p = 0.001, respectively), and CD28 in cis resulted in significantly higher levels of IL-2 secretion than in trans (p = 0.001).

 

Figure 2
View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 2. CD28 costimulation in trans does not promote localization of PKC{theta} to the cSMAC of the immunological synapse. T cells were stimulated with Ag presented by ProAd-ICAM in the absence of CD28 costimulation (none), with ProAd-ICAM in the presence of CD28 costimulation in trans with either anti-CD28-coated beads (beads) or B7-positive L cells (L cells), or with ProAd-ICAM-B7 to provide CD28 costimulation in cis (cis). T cell conjugates were stained for PKC{theta} (green) and analyzed by immunofluorescent microscopy. L cells were prelabeled with 7-amino-4-chloromethylcoumarin (CMAC; blue) to distinguish them from the ProAd-ICAM cells. A, Differential interference contrast images (DIC) and immunofluorescent images (PKC{theta}) are shown for representative conjugates. The position of T cells (T), ProAd-ICAM cells (APC), L cells (L), and anti-CD28-coated beads (B) are overlaid on the differential interference contrast image. Note that there are two T cells in the example with L cells providing CD28 costimulation in trans, only one of which is in contact with L cells. Both T cells display a diffuse pattern of PKC{theta} localization across the immunological synapse, unlike the focused localization of PKC{theta} in the cSMAC seen when CD28 costimulation is provided in cis. B and C, Individual conjugates were scored for recruitment of PKC{theta} to the immunological synapse (B) and for localization of PKC{theta} to the cSMAC (C). Data are shown as the percentage and SD of conjugates displaying PKC{theta} recruitment or cSMAC localization, respectively. The total number of conjugates scored over two to three separate experiments were as follows: none, n = 223; beads, n = 132; L cells, n = 87; and cis, n = 156. CD28 costimulation in trans significantly inhibits PKC{theta} recruitment to the immunological synapse (p = 0.001). In contrast, costimulation in cis enhances both recruitment of PKC{theta} to the synapse and localization to the cSMAC (p < 0.001).

 
These results suggested that the ability of CD28 to costimulate IL-2 expression in trans was not mediated through activation of PKC{theta}. To test this possibility directly, we compared the ability of CD28 in trans to costimulate CD4 T cells from WT and PKC{theta}-deficient DO11.10 mice (Fig. 3A). PKC{theta} was required for optimal IL-2 secretion when CD28 was provided in cis, as predicted from previous studies (24). However, T cells from WT and PKC{theta}-deficient mice induced similar levels of IL-2 secretion when CD28 was provided in trans. Similar results were obtained when CD28 costimulation in trans was provided by anti-CD28-coated beads or with cells expressing the natural ligand for CD28 (B7-positive L cells). CD28-deficient T cells were included as a negative control, as these cells are unable to respond to either cis or trans CD28 costimulation. Similar results were obtained when we tested previously activated and freshly isolated lymph node T cells (Fig. 3B). Interestingly, the greater potency of cis costimulation compared with trans costimulation was lost in the PKC{theta}-deficient T cells, suggesting that this increased potency of cis costimulation may be dependent on CD28-mediated recruitment of PKC{theta} to the cSMAC. Together, these results indicate that CD28 costimulation in trans is mediated through a PKC{theta}-independent pathway.


Figure 3
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 3. CD28 costimulation in trans is largely PKC{theta} independent. A, Previously activated T cells from WT ({blacksquare}), PKC{theta}-deficient ({cjs2108}), or CD28-deficient ({square}) DO11.10 mice were unstimulated (no Ag) or stimulated with Ag presented by ProAd-ICAM (Ag), by ProAd-ICAM in the presence of either anti-CD28-coated beads (beads) or L cells, or by ProAd-ICAM-B7 (cis). T cells were cultured for 48 h, and supernatants were assayed for IL-2 by capture ELISA. B, Freshly isolated T cells were analyzed as in A, except that trans costimulation was only provided by anti-CD28-coated beads. Data are the mean and SD of three independent experiments (except for L cells, which were only included in two of the three experiments). The absence of PKC{theta} does not significantly reduce the level of IL-2 secretion induced by CD28 costimulation in trans. In contrast, expression of PKC{theta} is required for the enhanced IL-2 secretion seen when CD28 costimulation is provided in cis (p = 0.03 in A and 0.01 in B).

 
CD28 costimulation in trans does not induce NF-{kappa}B nuclear translocation or IL-2 transcription

As discussed, CD28 costimulation through PI3K and the recruitment of PKC{theta} to the cSMAC has been implicated in the ability of CD28 to up-regulate IL-2 transcription. Because CD28 costimulation in trans is independent of PKC{theta}, it suggests that the ability of CD28 in trans to up-regulate IL-2 secretion is not mediated through the up-regulation of IL-2 transcription. To test the possibility directly, we first assessed nuclear localization of NF-{kappa}B (Fig. 4). CD28 costimulation in cis resulted in the induction of nuclear localization of NF-{kappa}B. In contrast, CD28 in trans had little effect on NF-{kappa}B activation. Similar results were obtained when nuclear localization of endogenous NF-{kappa}B was monitored by immunofluorescent staining (Fig. 4, A and B) or when an NF-{kappa}B p65-GFP fusion protein was retrovirally transduced to follow NF-{kappa}B activation (Fig. 4C). To assay, IL-2 transcription directly we used DO11.10 T cells that contain a transgenic IL-2-luciferase reporter construct (38). We have previously established that this transgene is a good indicator of endogenous IL-2 transcriptional activity (37). As expected from previous studies, cis costimulation resulted in transcriptional activation of the IL-2 enhancer (26). In contrast, only a modest increase in IL-2 transcriptional activation was detected with trans costimulation (Fig. 5). Collectively, these data indicate that CD28 engagement outside of the immunological synapse does not result in PKC{theta}-dependent activation of NF-{kappa}B and subsequent up-regulation of IL-2 transcription.


Figure 4
View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 4. CD28 in trans does not induce nuclear localization of NF-{kappa}B. A, T cell conjugates with ProAd-ICAM (none), with ProAd-ICAM and anti-CD28-coated beads (trans), or ProAd-ICAM-B7 (cis) were stained for p65 NF-{kappa}B (red). Nuclei were stained with Hoechst dye (blue). Examples of individual conjugates are shown. The T cell is the smaller cell orientated toward the left in each panel. Nuclear localization of NF-{kappa}B is detected by overlay of red p65 staining on the blue Hoechst stained nuclei. The APC on the right have constitutively active NF-{kappa}B. B, The percentage and SD of conjugates (n = 40–60 conjugates) displaying nuclear localization of NF-{kappa}B is shown. CD28 costimulation in cis, but not in trans, results in a significant increase in activation of NF-{kappa}B (p < 0.001). C, Conjugates were analyzed as described in A, except that T cells expressing a p65-GFP fusion protein were used to localize NF-{kappa}B. The T cell is the smaller cell orientated toward the lower left in each panel. The localization of the p65-GFP chimera is easier to discern because there is no staining in the APC.

 

Figure 5
View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 5. CD28 in trans does not up-regulate IL-2 transcription. Previously activated T cells from DO11.10 mice carrying the luciferase gene under the control of the IL-2 enhancer were unstimulated (–Ag) or stimulated with Ag (+) presented by ProAd-ICAM alone (–CD28), by ProAd-ICAM in the presence of anti-CD28-coated beads (trans), or by ProAd-ICAM-B7 (cis). T cells were cultured for 24 h, then lysed, and luciferase activity was measured in the supernatants. Luciferase activity is shown as the mean and SD of the fold induction above unstimulated T cells from three independent experiments. CD28 costimulation in trans results in a marginal increase in IL-2-luciferase expression (p = 0.04 in a one-tailed t test), whereas CD28 in cis results in a dramatic increase in IL-2-luciferase expression compared with both no CD28 (p = 0.007) and CD28 in trans (p = 0.005).

 
CD28 costimulation in trans can increase the stability of IL-2 mRNA

The ability of CD28 costimulation in trans to up-regulate IL-2 secretion, but not IL-2 transcription, indicates that trans costimulation must be mediated through posttranscriptional mechanisms. IL-2 can be regulated at several posttranscriptional events, including mRNA elongation, mRNA stability, translation, and secretion (7, 8, 40, 41, 42), but the best-described effect of CD28 costimulation is on mRNA stability. To determine the half-life of IL-2 mRNA, T cells were stimulated for 4 h, transcription was then blocked by addition of cyclosporin A, and IL-2 mRNA levels were determined by real-time PCR at different time points (Fig. 6). In the absence of CD28 costimulation IL-2 mRNA rapidly decays with a half-life of ~30 min. When costimulation is provided by CD28 in cis the half-life increases to ~90 min. Importantly, the increase in the half-life of IL-2 mRNA is similar when CD28 costimulation is provided in cis or in trans. Thus, engagement of CD28 outside of the immunological synapse is not sufficient to induce up-regulation of IL-2 transcription, but is able to transduce signals necessary for induction of IL-2 mRNA stability.


Figure 6
View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 6. Costimulation by CD28 in trans is mediated through IL-2 mRNA stability. Previously activated T cells were stimulated with Ag presented by ProAd-ICAM (no CD28), by ProAd-ICAM with anti-CD28-coated beads (trans), or by ProAd-ICAM-B7 (cis) for 4 h. IL-2 transcription was blocked by the addition of cyclosporin A. Cyclosporin A rapidly inhibits NFAT-dependent IL-2 transcription without affecting IL-2 mRNA stability (37 62 74 ). Levels of IL-2 mRNA were measured every hour by real-time PCR and shown as a percentage of IL-2 mRNA before the addition of cyclosporin A. The fold induction of IL-2 mRNA after the initial 4 h of activation was 3200 (no CD28), 5600 (trans), and 9800 (cis). This experiment is one representative experiment of two completed.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
We have recently proposed that there are two distinct pathways for CD28-mediated costimulation (26). The first is mediated through recruitment of PI3K to the cSMAC of the immunological synapse and results in the activation of PKC{theta}, nuclear translocation of NF-{kappa}B, and up-regulation of IL-2 transcription. Costimulation through this pathway may reflect integration of plasma membrane-proximal signals mediated through TCR and CD28 within the context of the immunological synapse. The second pathway of CD28 costimulation is not affected by mutation of the PI3K interaction site in CD28 and drives IL-2 production through stabilization of IL-2 mRNA. In this study, we show that when CD28 is engaged outside of the immunological synapse, only the second pathway of CD28 costimulation is induced. Thus, CD28-mediated up-regulation of IL-2 transcription requires membrane colocalization with TCR, possibly within the cSMAC of the immunological synapse. In contrast, CD28 signals that mediate IL-2 mRNA stability do not need to be colocalized with TCR, supporting the model that costimulation through this pathway may reflect signal integration downstream of the plasma membrane.

In addition to providing costimulation, there is evidence that CD28 can activate T cells in the absence of TCR engagement. Early studies showed that anti-CD28 cross-linking could induce a calcium response and anti-CD28 in combination with phorbol esters could induce IL-2 secretion and T cell proliferation (43, 44). More recently, it has been shown that CD28 cross-linking, in the absence of TCR engagement, can be sufficient to activate Vav and SLP-76 (45). However, these effects of anti-CD28 cross-linking can be restricted to certain cells and mAb epitopes. Recent data has provided some insight into this issue (46, 47). There are at least two major mAb epitopes expressed on CD28. Conventional Ab epitopes are localized near the B7 binding site and are thought to mimic natural ligand binding. The 37.51 mAb used in the present studies is a conventional Ab. Superagonists Ab epitopes have been mapped to a site that is proximal to the membrane and are functionally mitogenic, inducing IL-2 secretion and T cell proliferation. Interestingly, T cell activation by superagonist Abs can be mediated through PKC{theta} and NF-{kappa}B and up-regulation of IL-2 transcription (48). This suggests that CD28 is capable of independently activating T cells, but it is not clear whether these same signaling pathways mediate CD28 costimulation of TCR-derived signals. Furthermore, the relationship between CD28 engagement by superagonist Abs and by natural ligand binding is not understood. In the experiments reported, we show that trans costimulation using a conventional mAb or natural ligand is not mediated through PKC{theta} and NF-{kappa}B, but rather enhances IL-2 secretion through mRNA stability.

CD28 has been shown to function as a signal amplifier for TCR-transduced signals (1). Thus, the current model would suggest that colocalization of TCR and CD28 during cis costimulation would facilitate CD28 amplification of proximal TCR signals. The requirement for CD28-mediated activation of PI3K is consistent with this model because the product of PI3K, PIP3, would enhance the recruitment of PH domain-containing proteins, such as VAV, Itk, Akt, and PDK1, to the site of activation. In this case, colocalization of TCR and CD28 would create a signaling subdomain within the immunological synapse. However, Hünig and colleagues (47, 48, 49) have suggested an additional role for TCR/CD28 colocalization. They have shown that expression of the superagonist epitope on CD28 is enhanced following T cell activation, and activated T cells are more responsive to activation by superagonist anti-CD28 mAb. Thus, TCR signaling may induce a conformational change in CD28, which reveals the mitogenic Ab epitope and potentiates CD28 signaling. In this case, localization of CD28 to the site of TCR engagement may promote CD28 activation. This activity could be mediated by CD28 association with lipid raft domains and/or by access of CD28 to Lck. Lck binding to the polyproline rich region has been proposed to be the first step in CD28 signaling. Lck is then thought to phosphorylate Y170 on the CD28 cytosolic tail creating the binding site for the Src homology 2 domain of PI3K (50, 51). Thus, TCR/CD28 colocalization within the cSMAC may have a dual function, first in the activation of CD28 and subsequently in the signal integration of TCR- and CD28-derived signals.

In addition to enhancing proximal TCR-derived signals, CD28 signaling can also induce mRNA stability. The regulation of mRNA stability is largely controlled by AU-rich elements (ARE) within the 3' untranslated region (UTR). ARE-mediated mRNA degradation plays an important role in regulation of many genes (52, 53), including cytokines (8). The current model for regulated mRNA stability is that AU-binding proteins that induce mRNA instability, such as tristetraprolin (TTP), bind to the 3' UTR in unstimulated cells. TTP recruits the multicomponent exosome, allowing for deadenylation and 3' exonuclease digestion of the mRNA (54, 55). In the absence of ARE-mediated mRNA degradation, either by genetic disruption of TTP expression (56) or the deletion of the ARE from TNF (57), overexpression of TNF results in the induction of autoimmune inflammatory diseases. The stability of ARE-containing mRNAs can also be enhanced during cell activation events, although the mechanisms that mediate this stabilization are not well understood. One model that has been proposed is that cell signaling induces the recruitment of different AU-binding proteins, such as HuR, that may compete with TTP for binding to the 3' UTR and, thus, interfere with TTP-dependent recruitment of the exosome. T cell activation leads to an increase in expression of TTP and HuR, and TTP can bind to the AU-rich region in the IL-2 3' UTR and drive IL-2 mRNA degradation (58, 59). However, HuR does not recognize the specific AU-rich region in the IL-2 mRNA and another AU-binding protein, NF90, that can compete with TTP binding, has been implicated in signal-dependent IL-2 mRNA stabilization (60). Access of HuR and NF90 to target mRNA may be regulated by shuttling these nuclear proteins to the cytosol, and this process could be mediated by signal-dependent association of HuR with nuclear shuttle proteins (60, 61). MAPK activation has been implicated in the induction of mRNA stability. JNK can induce IL-2 and IL-3 mRNA stability (62, 63, 64); p38 has been implicated in the stabilization of IL-2, IL-6, IL-8, and TNF-{alpha} mRNA (65, 66, 67); and ERK can stabilize COX-2 mRNA in smooth muscle cells. Although there is some evidence of signal-dependent phosphorylation of AU-binding proteins, the exact role for these phosphorylation events in mediating mRNA stability is not clear (65, 68). Importantly, the proximal signals that are induced uniquely by CD28 to up-regulate mRNA stability have not been elucidated.

Trans costimulation has been proposed to play a role in immune responses to nonhemopoietic cells, such as in tumor and allograft rejection and autoimmunity. Using genetically deficient cells that eliminate the possibility of cis costimulation, it was directly demonstrated that trans costimulation could result in rejection of cardiac allografts (34). Nevertheless, any function of trans costimulation in vivo would be limited by two key factors. First, it requires separate interactions of a T cell with an Ag-bearing target cell and a non-Ag-bearing, B7-positive cell. Second, we show that trans costimulation does not induce a full component of CD28-mediated signals. Trans costimulation does not result in enhanced transcriptional activation and may be limited to the induction of mRNA stability. This finding could still play a key immunoregulatory role, not only to enhance IL-2 expression, but also to promote secretion of other proinflammatory cytokines, in particular TNF-{alpha} and IFN-{gamma}. Furthermore, the CD28 signaling pathway induced by trans costimulation may be sufficient for other CD28-mediated immune functions. Although it is not yet clear how many different signaling pathways are induced by CD28 (69, 70), as we discussed the PI3K pathway may be the major pathway associated with cis costimulation. In vivo reconstitution of CD28-deficient mice with CD28 mutants that cannot activate the PI3K pathway (Y170F) restores many, but not all, CD28-dependent functions. There are notable defects in up-regulation of Bcl-xL, radiation resistance, and graft-versus-host disease; however, T cell activation, IL-2 production, and proliferation are largely intact in mice expressing the Y170F mutation (71, 72, 73). In addition these mice generate WT levels of Th2 and T cell-dependent B cell responses, and normal numbers of CD25+ regulatory T cells (69, 70). Whether all of these functions can be induced by trans costimulation or are mediated through the regulation of mRNA stability will require additional investigation.


   Acknowledgments
 
We thank Dan Littman (New York University, New York, NY) for providing the PKC{theta}-deficient mice, Jeff Hanke (Pfizer, Groton, CT) for IL-2-LUC mice, and Ranjan Sen (Brandeis University, Waltham, MA) for providing the p65-GFP construct.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grants RO1-AI48237 and RO1-AI063418 from the National Institutes of Health (to J.M.), M.S.-L. was supported by National Institutes of Health Training Grant T32-AI007169. Back

2 Address correspondence and reprint requests to Dr. Jim Miller, Center for Vaccine Biology and Immunology, University of Rochester, Box 609, 601 Elmwood Avenue, Rochester, NY 14642-8609. E-mail address: jim_miller{at}urmc.rochester.edu Back

3 Abbreviations used in this paper: cSMAC, central supramolecular activation cluster; PKC{theta}, protein kinase C{theta}; WT, wild type; ARE, AU-rich element; UTR, untranslated region; TTP, tristetraprolin. Back

Received for publication December 1, 2005. Accepted for publication January 30, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Acuto, O., F. Michel. 2003. CD28-mediated co-stimulation: a quantitative support for TCR signaling. Nat. Rev. Immunol. 3: 939-951. [Medline]
  2. Lenschow, D., T. Walunas, J. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258. [Medline]
  3. Rudd, C. E.. 1996. Upstream-downstream: CD28 cosignaling pathways and T cell function. Immunity 4: 527-534. [Medline]
  4. Rudd, C. E., H. Schneider. 2003. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3: 544-556. [Medline]
  5. Harding, F., J. McArthur, J. Gross, D. Raulet, J. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607-609. [Medline]
  6. Jenkins, M., C. Chen, G. Jung, D. Mueller, R. Schwartz. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 144: 16-22. [Abstract]
  7. Fraser, J., B. Irving, G. Crabtree, A. Weiss. 1991. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251: 313-316. [Abstract/Free Full Text]
  8. Lindsten, T., C. H. June, J. A. Ledbetter, G. Stella, C. B. Thompson. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244: 339-343. [Abstract/Free Full Text]
  9. Boise, L., A. Minn, P. Noel, C. June, M. Accavitti, T. Lindsten, C. Thompson. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 3: 87-98. [Medline]
  10. Frauwirth, K., J. Riley, M. Harris, R. Parry, J. Rathmell, D. Plas, R. Elstrom, C. June, C. Thompson. 2002. The CD28 signalling pathway regulates glucose metabolism. Immunity 16: 769-777. [Medline]
  11. Rulifson, I., A. Sperling, P. Fields, F. Fitch, J. Bluestone. 1997. CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 158: 658-665. [Abstract]
  12. Viola, A., A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106. [Abstract]
  13. Michel, F., G. Attal-Bonnefoy, G. Mangino, S. Mise-Omata, O. Acuto. 2002. CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15: 935-945.
  14. Diehn, M., A. Alizadeh, O. Rando, C. Liu, K. Stankunas, D. Botstein, G. Crabtree, P. Brown. 2002. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. USA 99: 11796-11801. [Abstract/Free Full Text]
  15. Riley, J., M. Mao, S. Kobayashi, M. Biery, J. Burchard, G. Cavet, B. Gregson, C. June, P. Linsley. 2002. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. USA 99: 11790-11795. [Abstract/Free Full Text]
  16. Bromley, S. K., W. R. Burack, K. G. Johnson, K. Somersalo, T. N. Sims, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, M. L. Dustin. 2001. The immunological synapse. Annu. Rev. Immunol. 19: 375-396. [Medline]
  17. Dustin, M. L., A. C. Chan. 2000. Signaling takes shape in the immune system. Cell 103: 283-294. [Medline]
  18. Huppa, J., M. Davis. 2003. T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 3: 973-983. [Medline]
  19. van der Merwe, P. A.. 2002. Formation and function of the immunological synapse. Curr. Opin. Immunol. 14: 293-298. [Medline]
  20. Bromley, S., A. Iaboni, S. Davis, A. Whitty, J. Green, A. Shaw, A. Weiss, M. Dustin. 2001. The immunological synapse and CD28-CD80 interactions. Nat. Immunol. 2: 1159-1166. [Medline]
  21. Monks, C., H. Kupfer, I. Tamir, A. Barlow, A. Kupfer. 1997. Selective modulation of protein kinase C-{theta} during T cell activation. Nature 385: 83-86. [Medline]
  22. Altman, A., N. Isakov, G. Baier. 2000. Protein kinase C{theta}: a new essential superstar on the T-cell stage. Immunol. Today 21: 567-573. [Medline]
  23. Lee, K. Y., F. D’Acquisto, M. S. Hayden, J. H. Shim, S. Ghosh. 2005. PDK1 nucleates T cell receptor-induced signaling complex for NF-{kappa}B activation. Science 308: 114-118. [Abstract/Free Full Text]
  24. Sun, Z., C. W. Arendt, W. Ellmeier, E. M. Schaeffer, M. J. Sunshine, L. Gandhi, J. Annes, D. Petrzilka, A. Kupfer, P. L. Schwartzberg, D. R. Littman. 2000. PKC-{theta} is required for TCR-induced NF-{kappa}B activation in mature but not immature T lymphocytes. Nature 404: 402-407. [Medline]
  25. Huang, J., P. Lo, T. Zal, N. Gascoigne, B. Smith, S. Levin, H. Grey. 2002. CD28 plays a critical role in the segregation of PKC{theta} within the immunological synapse. Proc. Natl. Acad. Sci. USA 99: 9369-9373. [Abstract/Free Full Text]
  26. Sanchez-Lockhart, M., E. Marin, B. Graf, R. Abe, Y. Harada, C. E. Sedwick, J. Miller. 2004. Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways. J. Immunol. 173: 7120-7124. [Abstract/Free Full Text]
  27. Costello, P., M. Gallagher, D. Cantrell. 2002. Sustained and dynamic inositol lipid metabolism inside and outside the immunological synapse. Nat. Immunol. 3: 1082-1089. [Medline]
  28. Harriague, J., G. Bismuth. 2002. Imaging antigen-induced PI3K activation in T cells. Nat. Immunol. 3: 1090-1096. [Medline]
  29. Huppa, J., M. Gleimer, C. Sumen, M. Davis. 2003. Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat. Immunol. 4: 749-755. [Medline]
  30. Jenkins, M. K., J. D. Ashwell, R. H. Schwartz. 1988. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J. Immunol. 140: 3324-3330. [Abstract]
  31. Ding, L., E. M. Shevach. 1994. Activation of CD4+ T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation). Eur. J. Immunol. 24: 859-866. [Medline]
  32. Reiser, H., G. J. Freeman, Z. Razi-Wolf, C. D. Gimmi, B. Benacerraf, L. M. Nadler. 1992. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc. Natl. Acad. Sci. USA 89: 271-275. [Abstract/Free Full Text]
  33. Smythe, J. A., P. D. Fink, G. J. Logan, J. Lees, P. B. Rowe, I. E. Alexander. 1999. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. J. Immunol. 163: 3239-3249. [Abstract/Free Full Text]
  34. Mandelbrot, D. A., K. Kishimoto, H. Auchincloss, Jr, A. H. Sharpe, M. H. Sayegh. 2001. Rejection of mouse cardiac allografts by costimulation in trans. J. Immunol. 167: 1174-1178. [Abstract/Free Full Text]
  35. Zuckerman, L., L. Pullen, J. Miller. 1998. Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T cell activation. J. Immunol. 160: 3259-3268. [Abstract/Free Full Text]
  36. Razi-Wolf, Z., G. Freeman, F. Galvin, B. Benacerraf, L. Nadler, H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA 89: 4210-4214. [Abstract/Free Full Text]
  37. Abraham, C., J. Miller. 2001. Molecular mechanisms of IL-2 gene regulation following costimulation through LFA-1. J. Immunol. 167: 5193-5201. [Abstract/Free Full Text]
  38. Brunner, M. C., C. Chambers, F. Chan, J. Hanke, A. Winoto, J. Allison. 1999. CTLA-4-mediated inhibition of early events of T cell proliferation. J. Immunol. 162: 5813-5820. [Abstract/Free Full Text]
  39. Tam, W. F., L. H. Lee, L. Davis, R. Sen. 2000. Cytoplasmic sequestration of rel proteins by I{kappa}B{alpha} requires CRM1-dependent nuclear export. Mol. Cell. Biol. 20: 2269-2284. [Abstract/Free Full Text]
  40. Garcia-Sanz, J. A., D. Lenig. 1996. Translational control of interleukin 2 messenger RNA as a molecular mechanism of T cell anergy. J. Exp. Med. 184: 159-164. [Abstract/Free Full Text]
  41. Long, A., D. Kelleher, S. Lynch, Y. Volkov. 2001. Cutting edge: protein kinase Cbeta expression is critical for export of IL-2 from T cells. J. Immunol. 167: 636-640. [Abstract/Free Full Text]
  42. Umlauf, S., B. Beverly, O. Lantz, R. Schwartz. 1995. Regulation of interleukin 2 gene expression by CD28 costimulation in mouse T-cell clones: both nuclear and cytoplasmic RNAs are regulated with complex kinetics. Mol. Cell. Biol. 15: 3197-3205. [Abstract]
  43. Ledbetter, J. A., J. B. Imboden, G. L. Schieven, L. S. Grosmaire, P. S. Rabinovitch, T. Lindsten, C. B. Thompson, C. H. June. 1990. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 75: 1531-1539. [Abstract/Free Full Text]
  44. Ledbetter, J. A., C. H. June, L. S. Grosmaire, P. S. Rabinovitch. 1987. Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc. Natl. Acad. Sci. USA 84: 1384-1388. [Abstract/Free Full Text]
  45. Raab, M., S. Pfister, C. E. Rudd. 2001. CD28 signaling via VAV/SLP-76 adaptors: regulation of cytokine transcription independent of TCR ligation. Immunity 15: 921-933. [Medline]
  46. Evans, E. J., R. M. Esnouf, R. Manso-Sancho, R. J. Gilbert, J. R. James, C. Yu, J. A. Fennelly, C. Vowles, T. Hanke, B. Walse, et al 2005. Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 6: 271-279. [Medline]
  47. Lühder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Müller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, T. Hünig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966. [Abstract/Free Full Text]
  48. Dennehy, K. M., A. Kerstan, A. Bischof, J. H. Park, S. Y. Na, T. Hünig. 2003. Mitogenic signals through CD28 activate the protein kinase C{theta}-NF-{kappa}B pathway in primary peripheral T cells. Int. Immunol. 15: 655-663. [Abstract/Free Full Text]
  49. Bischof, A., T. Hara, C. H. Lin, A. D. Beyers, T. Hünig. 2000. Autonomous induction of proliferation, JNK and NF-{alpha}B activation in primary resting T cells by mobilized CD28. Eur. J. Immunol. 30: 876-882. [Medline]
  50. Holdorf, A. D., J. M. Green, S. D. Levin, M. F. Denny, D. B. Straus, V. Link, P. S. Changelian, P. M. Allen, A. S. Shaw. 1999. Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation. J. Exp. Med. 190: 375-384. [Abstract/Free Full Text]
  51. Tavano, R., G. Gri, B. Molon, B. Marinari, C. E. Rudd, L. Tuosto, A. Viola. 2004. CD28 and lipid rafts coordinate recruitment of Lck to the immunological synapse of human T lymphocytes. J. Immunol. 173: 5392-5397. [Abstract/Free Full Text]
  52. Raghavan, A., M. Dhalla, T. Bakheet, R. L. Ogilvie, I. A. Vlasova, K. S. Khabar, B. R. Williams, P. R. Bohjanen. 2004. Patterns of coordinate down-regulation of ARE-containing transcripts following immune cell activation. Genomics 84: 1002-1013. [Medline]
  53. Raghavan, A., R. L. Ogilvie, C. Reilly, M. L. Abelson, S. Raghavan, J. Vasdewani, M. Krathwohl, P. R. Bohjanen. 2002. Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes. Nucleic Acids Res. 30: 5529-5538. [Abstract/Free Full Text]
  54. Kracht, M., J. Saklatvala. 2002. Transcriptional and post-transcriptional control of gene expression in inflammation. Cytokine 20: 91-106. [Medline]
  55. Shim, J., M. Karin. 2002. The control of mRNA stability in response to extracellular signals. Mol. Cells 14: 323-331. [Medline]
  56. Carbello, E., W. Lai, P. Blackshear. 1998. Feedback inhibition of macrophage tumor necrosis factor-{alpha} production by tristertraprolin. Science 281: 1001-1005. [Abstract/Free Full Text]
  57. Kontoyiannis, D., M. Pasparakis, T. T. Pizarro, F. Cominelli, G. Kollias. 1999. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10: 387-398. [Medline]
  58. Ogilvie, R. L., M. Abelson, H. H. Hau, I. Vlasova, P. J. Blackshear, P. R. Bohjanen. 2005. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J. Immunol. 174: 953-961. [Abstract/Free Full Text]
  59. Raghavan, A., R. Robinson, J. McNabb, C. Miller, D. Williams, P. Bohjanen. 2001. HuA and tristetraprolin are induced following T cell activation and display distinct overlapping RNA binding specificities. J. Biol. Chem. 276: 47958-47965. [Abstract/Free Full Text]
  60. Shim, J., H. Lim, J. Yates, K. M. . 2002. Nuclear export of NF90 is required for interleukin-2 mRNA stabilization. Mol. Cell 10: 1331-1344. [Medline]
  61. Brennan, C. M., I. Gallouzi, J. Steitz. 2000. Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J. Cell Biol. 151: 1-14. [Free Full Text]
  62. Chen, C. Y., F. Del Gatto-Konczak, Z. Wu, M. Karin. 1998. Stabilization of IL-2 mRNA by the c-Jun NH2-terminal kinase pathway. Science 280: 1945-1949. [Abstract/Free Full Text]
  63. Chen, C. Y., R. Gherzi, J. Andersen, G. Gaietta, K. Jurchott, H. Royer, M. Mann, M. Karin. 2000. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev. 14: 1236-1248. [Abstract/Free Full Text]
  64. Ming, X. F., M. Kaiser, C. Moroni. 1998. c-jun N-terminal kinase is involved in AUUUA-mediated IL-3 mRNA turnover in mast cells. EMBO J. 17: 6039-6048. [Medline]
  65. Mahtani, K., M. Brook, J. Dean, G. Sully, J. Saklatvala, A. Clark. 2001. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor {alpha} mRNA stability. Mol. Cell. Biol. 21: 6461-6469. [Abstract/Free Full Text]
  66. Mestas, J., S. P. Crampton, T. Hori, C. C. Hughes. 2005. Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. Int. Immunol. 17: 737-747. [Abstract/Free Full Text]
  67. Winzen, R., M. Kracht, B. Ritter, A. Wilheim, C. Chen, A. Shyu, M. Muller, M. Gaestel, K. Resch, H. Holtmann. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase activated protein kinase-2 and an AU-rich region-targeted mechanism. EMBO J. 18: 4969-4980. [Medline]
  68. Wilson, G., J. Lu, K. Sutphen, Y. Sun, Y. Huynh, G. Brewer. 2003. Regulation of AU-rich element directed mRNA turnover involving reversible phosphorylation of AUF1. J. Biol. Chem. 278: 33029-33038. [Abstract/Free Full Text]
  69. Andres, P., K. Howland, A. Nirula, L. Kane, L. Barron, D. Dresnek, A. Sadra, J. Imboden, A. Weiss, A. Abbas. 2004. Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation. Nat. Immunol. 5: 435-442. [Medline]
  70. Tai, X., M. Cowan, L. Feigenbaum, A. Singer. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6: 152-162. [Medline]
  71. Burr, J., N. Savage, G. Messah, S. Kimzey, A. Shaw, R. Arch, J. Green. 2001. Cutting edge: distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-xL. J. Immunol. 166: 5331-5335. [Abstract/Free Full Text]
  72. Harada, Y., M. Tokushima, Y. Matsumoto, S. Ogawa, M. Otsuka, K. Hayashi, B. Weiss, C. June, R. Abe. 2001. Critical requirement for the membrane-proximal tyrosine residue for CD28-mediated costimulation in vivo. J. Immunol. 166: 3797-3803. [Abstract/Free Full Text]
  73. Okkenhaug, K., L. Wu, K. Garza, J. La Rose, W. Khoo, B. Odermatt, T. Mak, P. Ohashi, R. Rottapel. 2001. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat. Immunol. 2: 325-332. [Medline]
  74. Ragheb, J. A., M. Deen, R. Schwartz. 1999. CD28-mediated regulation of mRNA stability requires sequences within the coding region of the IL-2 mRNA. J. Immunol. 163: 120-129. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Shen, V. K. Thomas, M. L. Dustin, and L. C. Kam
From the Cover: Micropatterning of costimulatory ligands enhances CD4+ T cell function
PNAS, June 3, 2008; 105(22): 7791 - 7796.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Graf, T. Bushnell, and J. Miller
LFA-1-Mediated T Cell Costimulation through Increased Localization of TCR/Class II Complexes to the Central Supramolecular Activation Cluster and Exclusion of CD45 from the Immunological Synapse
J. Immunol., August 1, 2007; 179(3): 1616 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
K. S. A. Khabar
Rapid transit in the immune cells: the role of mRNA turnover regulation
J. Leukoc. Biol., June 1, 2007; 81(6): 1335 - 1344.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanchez-Lockhart, M.
Right arrow Articles by Miller, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanchez-Lockhart, M.
Right arrow Articles by Miller, J.